

# Bladder Cancer (Urothelial) Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

**Biomarkers/Characteristics:** (select all that apply)

Microsatellite instability: \_\_dMMR/MSI-H \_\_MSI-L \_\_Not reported Platinum Resistant/Refractory? \_\_ Yes \_\_ No \_\_ Not reported

NTRK Fusion: \_\_Positive \_\_Negative \_\_Not reported

## Neoadjuvant Therapy/Perioperative Therapy

- Clinical Stage II, III, or IV Without Evidence of Metastases (M0)
  - ddMVAC\***: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with G-CSF
  - Durvalumab (Imfinzi), gemcitabine, and cisplatin followed by durvalumab (Imfinzi)
  - Enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda)

## Adjuvant Therapy

- Stage 0 (Ta, Tis) or Stage I or Recurrent Disease
  - Following Transurethral Resection of Bladder Tumor (TURBT) OR Resection of Recurrent/Persistent Disease, 1-2 sets of treatment
    - BCG**: Bacillus Calmette-Guerin, intravesical
  - For low-grade histology only, Following TURBT OR Resection of Recurrent/Persistent Disease
    - Gemcitabine (Gemzar), intravesical
- Stages II-IVA (after radical resection)
  - Nivolumab (Opdivo)

## First Line of Therapy (1st Line)

- Stages IV or Recurrent
  - Enfortumab vedotin (Padcev) and pembrolizumab (Keytruda)

\* Administration of ddMVAC is limited to 6 cycles

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue  
South Tower – Suite 800 Chicago, IL 60631

Last review: 2/10/2026 | Effective date: 4/20/2026

© 2026 Carelon Medical Benefits Management